Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study

View ORCID ProfileKei Nakashima, Masayuki Ishida, Hiroyuki Matsui, Chihiro Yoshida, Tatsuya Nagai, Minoru Shiraga, Hiroshi Nakaoka, Yoshihito Otsuka, Yu Nakagama, Natsuko Kaku, View ORCID ProfileYuko Nitahara, Yasutoshi Kido, Yoshio Hirota
doi: https://doi.org/10.1101/2022.06.23.22276536
Kei Nakashima
aDepartment of Pulmonology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kei Nakashima
  • For correspondence: kei.7.nakashima{at}gmail.com
Masayuki Ishida
bDepartment of Pulmonology, Chikamori Hospital, 1-16 Okawasuji, Kochi, 780-8522, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroyuki Matsui
cClinical Research Support Office, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chihiro Yoshida
aDepartment of Pulmonology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuya Nagai
aDepartment of Pulmonology, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minoru Shiraga
bDepartment of Pulmonology, Chikamori Hospital, 1-16 Okawasuji, Kochi, 780-8522, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Nakaoka
bDepartment of Pulmonology, Chikamori Hospital, 1-16 Okawasuji, Kochi, 780-8522, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihito Otsuka
dDepartment of Laboratory medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba 296-8602, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Nakagama
eDepartment of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natsuko Kaku
eDepartment of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuko Nitahara
eDepartment of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yuko Nitahara
Yasutoshi Kido
eDepartment of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshio Hirota
fClinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co. LTA), 3-5-1 Kashii-Teriha, Higashi-ku, Fukuoka, 813-0017 Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction This study assessed the immunogenicity and safety of BNT162b2 mRNA vaccine in lung cancer patients receiving anticancer treatment using two immunoassays. Methods: We enrolled lung cancer patients receiving anticancer treatment and non-cancer patients with chronic diseases; all participants were fully vaccinated with the BNT162b2 vaccine. Blood samples were collected before the first and second vaccinations and 4 ± 1 weeks after the second vaccination. Anti-acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein S1 subunit receptor-binding domain antibody titers were measured using the Architect SARS-CoV-2 IgG II Quant (Abbott Laboratory) and Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics).

Results Fifty-five lung cancer patients and 38 non-cancer patients were included in the immunogenicity analysis. Lung cancer patients showed significant increase in the geometric mean antibody titer, which was significantly lower than that in the non-cancer patients after the first (30 vs. 121 AU/mL, p<0.001 on Architect; 4.0 vs 1.2 U/mL, p<0.001, on Elecsys) and second vaccinations (1632 vs. 3472 AU/mL, p=0.005, on Architect; 213 vs 573 A/mL, p=0.002, on Elecsys). The adjusted odds ratio (OR) for seroprotection was significantly lower in the lung cancer patients. Analysis of the anticancer treatment types showed that the adjusted OR for seroprotection was significantly lower in lung cancer patients receiving cytotoxic agents. Lung cancer patients showed no increase in the number of adverse reactions.

Conclusions BNT162b2 vaccination in lung cancer patients undergoing anticancer treatment significantly increased antibody titers and showed acceptable safety. However, the immunogenicity in these patients could be inadequate compared with that in non-cancer patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by a Grant-in-Aid for the Investigation of the Promotion of Health Labor Administration (Research Project for the Promotion of Policies for Emerging and Re-emerging Infectious Diseases and Immunization; Principal Investigator: Yoshio Hirota; Grant Number: 20HA2001), Japan Society for the Promotion of Science KAKENHI [Grant Number: 22K15927 (Yu Nakagama)] and Japan Agency for Medical Research and Development (AMED) [Grant Numbers: JP20he1122001 (Yasutoshi Kido) and JP20jk0110021 (Yu Nakagama)]. We received support from Osaka City University's "Special Reserves" fund for COVID-19.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Hakata Clinic Institutional Review Board

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding This study was supported by a Grant-in-Aid for the Investigation of the Promotion of Health Labor Administration (Research Project for the Promotion of Policies for Emerging and Re-emerging Infectious Diseases and Immunization; Principal Investigator: Yoshio Hirota; Grant Number: 20HA2001), Japan Society for the Promotion of Science KAKENHI [Grant Number: 22K15927 (Yu Nakagama)] and Japan Agency for Medical Research and Development (AMED) [Grant Numbers: JP20he1122001 (Yasutoshi Kido) and JP20jk0110021 (Yu Nakagama)]. We received support from Osaka City University’s “Special Reserves” fund for COVID-19.

  • Disclosure of potential conflicts of interest The authors declare that they have no conflicts of interest.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

  • Abbreviations

    CI,
    confidence interval;
    COVID-19,
    coronavirus disease;
    GMT,
    geometric mean antibody titer;
    ICIs,
    immune-checkpoint inhibitors;
    OR,
    odds ratio;
    sP,
    seroprotection rate;
    TKIs;
    tyrosine kinase inhibitors.
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted June 26, 2022.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study
    Kei Nakashima, Masayuki Ishida, Hiroyuki Matsui, Chihiro Yoshida, Tatsuya Nagai, Minoru Shiraga, Hiroshi Nakaoka, Yoshihito Otsuka, Yu Nakagama, Natsuko Kaku, Yuko Nitahara, Yasutoshi Kido, Yoshio Hirota
    medRxiv 2022.06.23.22276536; doi: https://doi.org/10.1101/2022.06.23.22276536
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study
    Kei Nakashima, Masayuki Ishida, Hiroyuki Matsui, Chihiro Yoshida, Tatsuya Nagai, Minoru Shiraga, Hiroshi Nakaoka, Yoshihito Otsuka, Yu Nakagama, Natsuko Kaku, Yuko Nitahara, Yasutoshi Kido, Yoshio Hirota
    medRxiv 2022.06.23.22276536; doi: https://doi.org/10.1101/2022.06.23.22276536

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (430)
    • Allergy and Immunology (756)
    • Anesthesia (221)
    • Cardiovascular Medicine (3294)
    • Dentistry and Oral Medicine (364)
    • Dermatology (279)
    • Emergency Medicine (479)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
    • Epidemiology (13376)
    • Forensic Medicine (19)
    • Gastroenterology (899)
    • Genetic and Genomic Medicine (5153)
    • Geriatric Medicine (482)
    • Health Economics (783)
    • Health Informatics (3268)
    • Health Policy (1140)
    • Health Systems and Quality Improvement (1190)
    • Hematology (431)
    • HIV/AIDS (1017)
    • Infectious Diseases (except HIV/AIDS) (14627)
    • Intensive Care and Critical Care Medicine (913)
    • Medical Education (477)
    • Medical Ethics (127)
    • Nephrology (523)
    • Neurology (4925)
    • Nursing (262)
    • Nutrition (730)
    • Obstetrics and Gynecology (883)
    • Occupational and Environmental Health (795)
    • Oncology (2524)
    • Ophthalmology (724)
    • Orthopedics (281)
    • Otolaryngology (347)
    • Pain Medicine (323)
    • Palliative Medicine (90)
    • Pathology (543)
    • Pediatrics (1302)
    • Pharmacology and Therapeutics (550)
    • Primary Care Research (557)
    • Psychiatry and Clinical Psychology (4212)
    • Public and Global Health (7504)
    • Radiology and Imaging (1705)
    • Rehabilitation Medicine and Physical Therapy (1013)
    • Respiratory Medicine (980)
    • Rheumatology (480)
    • Sexual and Reproductive Health (497)
    • Sports Medicine (424)
    • Surgery (548)
    • Toxicology (72)
    • Transplantation (236)
    • Urology (205)